1. Van Neste L, Partin AW, Stewart GD, Epstein JI, Harrison DJ, and Van Criekinge W. Risk Score Predicts High-Grade Prostate Cancer in DNA-Methylation Positive, Histopathologically Negative Biopsies. The Prostate. 2016 Sep;176(12):1078-87.
  2. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Track BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. The Joumal of Urology. 2014 Oct;192(4):1081-7.
  3. Merril J. Prostate cancer market snapshot: more than provenge. The Pink Sheet. November 22, 2010. Elsevier Business Intelligence Publications and Products. https://www.pharmamedtechbi.com/publications/the-pink-sheet/72/47/prostate-cancer-market-snapshot-more-then-provenge. Accessed January 29, 2013.
  4. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy–part I: early detection and diagnosis of prostate cancer. Urology 2001; 57:217.
  5. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147:841.
  6. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270:948.
  7. Crawford ED, DeAntoni EP, Etzioni R, et al. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47:863.
  8. Taneja et al.: The American Urological Association (AUA) Optimal Techniques of Prostate Biopsy and Specimen Handling. 2013.
  9. Shen et al.: Three-Dimensional Sonography With Needle Tracking – Role in Diagnosis and Treatment of Prostate Cancer. J. Ultrasound Med. 2008; Jun; 27(6): 895-905.
  10. Rabets JC et al.: Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. The Journal of Urology. 2004; Jul; 172(1): 94–97.
  11. Kronz JD et al.: Predicting cancer following a diagnosis of high-¬‐grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-¬‐up biopsy. American Journal of Surgical Pathology 2001; Aug 25(8): 1079–1085.
  12. Based on MDxHealth management estimates taken from publicly available Medicare and other data.
  13. Trock BJ et al.: Evaluation of GSTP1 and APC Methylation as Indicators for Repeat Biopsy in a High-risk Cohort of Men with Negative Initial Prostate Biopsies. British Journal of Urology International 2012; July 110(1): 56-62.
  14. National Cancer Institute. Surveillance, Epidemiology and End Results. 2014 Prostate Cancer Statistics http://seer.cancer.gov/statfacts/html/prost.html.
  15. Pinsky PF, Crawford ED, Kramer BS, et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007;4:775-779.
  16. Mosquera J-M, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-4711.
  17. Slaughter DP et al.: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; Sep; 6(5): 963–8.
  18. Braakhuis BJ et al.: A Genetic Explanation of Slaughter’s Concept of Field Cancerization: Evidence and Clinical Implications. Cancer Res. 2003. Apr 15; 63(8): 1727-30.
  19. Van Neste L et al.: The Epigenetic Promise for Prostate Cancer Diagnosis. The Prostate 2011; 1; 72(11): 1248-61.
  20. Trujillo KA et al.: Markers of Field Cancerization: Proposed Clinical Applications in Prostate Biopsies. Prostate Cancer 2012; 2012:302894.
  21. Henrique R et al.: Epigenetic Heterogeneity of High-Grade Prostatic Prostate Carcinogenesis Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Mol. Cancer Res. 2006; Jan; 4(1): 1-8.
  22. Zhou M et al.: Quantitative GSTP1 Methylation Levels Correlate with Gleason Grade and Tumor Volume in Prostate Needle Biopsies. J. Urol. 2004; Jun; 171 (6PT 1): 2195-8.